Akari Therapeutics, Plc (AKTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Akari Therapeutics, Plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Akari Therapeutics, Plc (AKTX) has returned -55.45% so far this year and -89.62% over the past 12 months. Over the last ten years, AKTX has returned -54.58% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Sep 21, 2015, AKTX's average daily return is -0.11%, while the average monthly return is -3.39%.

Historically, 37% of months were positive and 63% were negative. The best month was Mar 2019 with a return of +97.8%, while the worst month was May 2017 at -59.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.

On a daily basis, AKTX closed higher 42% of trading days. The best single day was Mar 13, 2019 with a return of +224.2%, while the worst single day was Dec 16, 2025 at -38.3%.

Akari Therapeutics, Plc has an annualized alpha of -29.85%, beta of 0.55, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 22, 2015.

• This stock participated in 206.26% of S&P 500 Index downside but only -80.44% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.55 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AKTX ranks 4 for risk / return — in the bottom 4% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Akari Therapeutics, Plc (AKTX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Akari Therapeutics, Plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akari Therapeutics, Plc was 99.98%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Akari Therapeutics, Plc drawdown is 99.98%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Akari Therapeutics, Plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Akari Therapeutics, Plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.